## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -5.9% below STRENGTH zone (4.0-10.0%); PEG 1.97 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($190.13)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Marshall Wace LLP Buys 309,335 Shares of Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251205T125641 | Bullish | Relevance: 100%
- Marshall Wace LLP increased its stake in Cardinal Health, Inc. (NYSE:CAH) by 19.1% in the second quarter, now owning 1,930,967 shares valued at $324,402,000. Several other institutional investors also adjusted their positions in CAH, with many increasing their holdings. Cardinal Health recently reported strong earnings, beating analyst estimates, and declared a quarterly dividend of $0.5107 per share.

**2. 3 No-Brainer Dividend Stocks to Buy Right Now**
- Source: Finviz | 20251205T063900 | Bullish | Relevance: 100%
- This article identifies three dividend stocks — Cardinal Health (CAH), Chevron (CVX), and Target (TGT) — that offer compelling long-term prospects for dividend investors. It highlights Cardinal Health's successful transformation and potential for aggressive dividend growth, Chevron's renewed focus on shareholder value, and Target's sustainable high yield and potential for future substantial dividend increases amid a turnaround. The author emphasizes considering dividend growth track record and safety, not just yield, when evaluating dividend investments.

**3. Cardinal Health (CAH) Stock Pulls Back From Record Highs: Latest News, Forecasts and Investment Outlook as of December 3, 2025**
- Source: ts2.tech | 20251203T230739 | Somewhat-Bullish | Relevance: 100%
- Cardinal Health (CAH) stock has experienced a pullback after a significant rally in 2025, with shares down 2.64% on December 3, 2025. Despite this recent weakness, the company has delivered strong year-to-date returns and robust Q1 FY 2026 results, driven by specialty pharmaceuticals and strategic acquisitions like Solaris Health. Analyst sentiment remains largely positive with "Buy" ratings and target price increases, though valuation concerns and execution risks are noted by more cautious investors, suggesting a potential consolidation phase for the stock.

**4. Key facts: Cardinal Health prioritizes high ROI; officers surrender shares**
- Source: TradingView | 20251203T210623 | Somewhat-Bullish | Relevance: 100%
- Cardinal Health (CAH) focuses its capital deployment strategy on high return on investment opportunities, emphasizing shareholder returns and strategic mergers and acquisitions. Recently, on December 2, 2025, company officers surrendered 1,949 shares to cover costs associated with exercising options and tax liabilities, as reported to the SEC.

**5. What Recent Specialty Pharma Moves Mean for Cardinal Health’s Stock Valuation**
- Source: Sahm | 20251203T111142 | Somewhat-Bullish | Relevance: 100%
- Cardinal Health's stock has seen significant growth, climbing 76.2% year-to-date, driven by its expansion into specialty pharmaceuticals and distribution partnerships. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 55%, its current Price-to-Earnings (PE) ratio of 31x is slightly above its fair level of 29.4x, indicating that the valuation is "about right" given its financial profile and future potential. The article encourages investors to use "Narratives" to customize valuation models based on their own assumptions about the company's future.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-05 | Wells Fargo | $221 | $185 | +19% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-05 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.1% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.97 elevated, pricing in significant growth expectations. Analyst sentiment positive (1 raises, avg +19%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $49.5B |
| Beta | 0.64 |
| 52W Range | $117.53 - $214.93 |
| Short Interest | 2.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.97 |
| Forward P/E | 17.9 |
| Current P/E | 20.2 |
| YoY Growth | 12.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.2% to -5.9% (-6.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.9pp (needs >4.0% for momentum thesis). AM_20 at -3.7% indicates price below own 20MA trend. Underperforming sector by 3.6pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.27x) but short-term weakness (below SMA20). MACD histogram bearish (-3.02), momentum weakening. RSI neutral at 52. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.91% (CS: 7) | Weak |
| RSI_14 | 51.6 | Neutral |
| MACD Histogram | -3.02 | Bearish |
| vs SMA20 | 0.963x | Below |
| vs SMA50 | 1.096x | Above |
| vs SMA200 | 1.275x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $198.83
- **Stop Loss:** $190.13 (4.4% risk)
- **Target:** $207.53 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 57
- **Position Value:** $11,333.31
- **Portfolio %:** 11.33%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.3% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*